gastric bypass vs glp 1 GLP-1 Bariatric Surgery Study: 93.4% of Bariatric Patients Would Do the Surgery Again Interest in Treatment with GLP-1

Semaglutide was approved for weight management in 2021, while tirzepatide followed in 2023

In clinical trials of incretin-based therapies, gastrointestinal symptoms are often monitored during dose escalation and may vary by dose, schedule, and individual tolerance

Does the Medicare Bridge Program cover semaglutide

The most commonly reported side effects include: Nausea Diarrhoea Vomiting Mild stomach discomfort Constipation In TRIUMPH-1, treatment discontinuation due to adverse events rose with dose: approximately 4.1% at 4 mg, 6.9% at 9 mg, and 11.3% at 12 mg , compared with 4.9% in the placebo group

BMC Complement Altern Med

Glucagon-like peptide-1: New regulator in lipid metabolism